Expert Solutions in Drug Formulation Development

Expert Solutions to these Challenging Scenarios

Challenge:

 

Client #1 required a common formulation for a family of four compounds that employed a clear, water-based vehicle to increase topical bioavailability.

  

Velesco Solution:

 

  • Within two days, Velesco developed a common formulation applicable to all five compounds to be dosed at three strengths each.
  • All four compound formulations demonstrated significant improvement versus control.
  • Timely delivery of the formulation allowed the client to meet their tight timelines for an animal study.

Challenge:

 

Client #2 had a poorly soluble compound which they needed in a vehicle acceptable for oral, intraperitoneal, and intravenous use.

  

Velesco Solution:

 

  • Within one week, Velesco successfully developed a formulation that met the client's target concentration, was isotonic, well tolerated by the target animal species, and was acceptable for all three routes of administration.
  • The formulation was simple to prepare and demonstrated 2 week stability at ambient storage.

Challenge:

 

Client #3 had a poorly soluble compound which they wanted formulated as a clear solution/microemulsion at high concentration for oral use in tox studies.

  

Velesco Solution:

 

  • Within one day, Velesco developed a formulation that met the client's target concentration, was a lipid-based self-emulsifying drug delivery system (SEDDS), stable for three weeks at ambient storage, and had potential for further development as a soft-gel formulation.
  • Client requested development of additional oil/water microemulsion formulations at high concentration.  Velesco quickly developed two additional formulations to meet these requirements.  The oil/water microemulsion also demonstrated good stability.

Challenge:

Client #4 had a poorly soluble, non-ionizable compound and required a high dose injectable formulation for animal studies.


Velesco Solution:

  • Regular solvent mixtures were unable to achieve the required dose, but the precipitation characteristics suggested nucleation inhibitors may work.
  • A successful non-toxic formulation containing anti-nucleation polymers was developed.
  • A successful animal study was performed.

News and Events

Velesco CEO Dave Barnes will attend the Global Clinical Supplies Group meeting in April.

 

Dave Barnes Featured in Pharmoutsourcing article!

 

 

Follow VelescoPharma on Twitter  LinkedIn IN Icon 25px
aaps logo TN

734-527-9125